Voyager Therapeutics shares are trading higher after the company reported strong fourth-quarter 2025 financial results, highlighted by significant pipeline progress and a robust cash position expected to sustain operations into 2028.

MacroGenics shares are trading higher after the company reported stable 2025 financial results and highlighted upcoming data disclosures from its innovative antibody-drug conjugate programs, affirming a strong cash position expected to support operations into late 2027.

TTEC shares are trading higher after the company won multiple honors at the 2026 Stevie Awards, recognizing their innovation in AI-driven customer experience and sales excellence.

LifeMD shares are trading higher after the company reported a 25% increase in full-year revenue for 2025 and a 348% rise in fourth-quarter adjusted EBITDA, alongside strategic expansions in its weight management and women’s health offerings.

La Rosa Holdings Corp. shares are trading lower after an investor rights law firm, Halper Sadeh LLC, announced investigations into the company's proposed merger with Consensus Core Technologies, raising concerns about the fairness of the deal for shareholders.

Optical Cable Corporation shares are trading higher after the company reported a 4.4% increase in net sales and a 16.1% increase in gross profit for the first quarter of fiscal year 2026.

Nuwellis shares are trading higher after the company reported positive fourth-quarter financial results, highlighted by a 208% increase in U.S. console sales and improved gross margins, alongside strategic acquisitions and leadership changes.

Rackspace Technology shares are trading higher after the company announced a strategic partnership with Uniphore to deliver the industry's first Infrastructure-to-Agents architecture, aimed at accelerating enterprise AI adoption.

Identiv shares are trading higher after the company announced an exclusive supply agreement with IFCO to develop and supply next-generation BLE smart labels.

Kohl's shares are trading lower after the company reported a 3.9% decrease in fourth-quarter net sales and a 4.0% decline in fiscal year 2025 net sales. The company also noted a reduction in comparable sales and gross margin, contributing to its negative stock price movement.

HeartBeam shares are trading higher after the company announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to accelerate the joint development of next-generation AI-ECG algorithms.

BioNTech shares are trading lower after the announcement that its co-founders plan to establish a new independent company, potentially diluting focus and resources from BioNTech's mRNA innovations.

MiNK Therapeutics shares are trading higher after announcing a strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with up to $1.1 million in funding and a potential for commercial revenue participation.

Cue Biopharma shares are trading higher after the company announced it will present new in vitro data demonstrating the therapeutic potential of CUE-401 at the World Immune Regulation Meeting 2026.

Yalla Group shares are trading lower after the company reported a decrease in paying users and quarterly revenue for Q4 2025 compared to the same period last year.

Arq shares are trading lower after the company reported significant GAC production start-up costs and a $45 million impairment charge related to its Corbin facility.

FreightCar America shares are trading lower after reporting a fourth-quarter net loss of $16.6 million due to significant non-cash adjustments, along with decreased revenues and lower gross margins compared to the previous year.

Mobix Labs shares are trading lower despite positive developments in its defense sector technologies, as investors weigh the risks and uncertainties outlined in the company’s forward-looking statements.

Cartesian Therapeutics shares are trading higher after the company announced that enrollment is progressing in their Phase 3 AURORA trial for Descartes-08 in myasthenia gravis.

Acurx Pharmaceuticals shares are trading higher after the announcement of new clinical trials for ibezapolstat, aimed at treating and preventing recurrent C. difficile infections.